Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Limited has successfully launched a fundraising effort through the issuance of A$650 million in convertible notes, which are set to mature in 2029. These notes, which will increase total liabilities and equity after accounting for transaction costs, have the potential to convert into 34,759,358 ordinary shares, diluting existing equity if exercised. The company is ensuring compliance with all relevant disclosure obligations and has made recent financial and disclosure documents available for public access.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
